van Rey Farida, Heesakkers John
Department of Urology, The Radboud University Nijmegen Medical Centre, Geert Grooteplein 10, 6500 GA Nijmegen, The Netherlands.
Adv Urol. 2011;2011:834753. doi: 10.1155/2011/834753. Epub 2011 May 5.
Objective. To assess the efficacy and the effect on Qol of solifenacin for the treatment of OAB in MS patients. Patients and Methods. Thirty MS patients suffering from OAB were treated with solifenacin 5/10 mg for 8 weeks. The first 4 weeks patients received solifenacin 5 mg. At week 4 patients could request a dose increase to 10 mg. The efficacy was evaluated at 8 weeks. Results. After 4 weeks of treatment, 28 patients reported acceptable or no side effects. 17 continued the study with the 10 mg dosage, and 11 stayed on 5 mg solifenacin. Two patients withdrew from the study due to side effects. Solifenacin 5/10 mg for 8 weeks resulted in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement. Conclusions. Solifenacin is effective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).
目的。评估索利那新治疗多发性硬化症（MS）患者膀胱过度活动症（OAB）的疗效及对生活质量（QoL）的影响。患者与方法。30例患有OAB的MS患者接受5/10毫克索利那新治疗8周。前4周患者服用5毫克索利那新。在第4周时，患者可要求增加剂量至10毫克。在第8周评估疗效。结果。治疗4周后，28例患者报告可接受或无副作用。17例患者继续以10毫克剂量进行研究，11例患者继续服用5毫克索利那新。2例患者因副作用退出研究。与基线相比，服用5/10毫克索利那新8周使排尿次数和每日使用尿垫数量显著减少。排尿前尿急的严重程度也显著降低，每次尿量增加。30例患者中有20例在研究结束后选择继续索利那新治疗。大多数患者报告整体生活质量有所改善。结论。索利那新对治疗有OAB症状的MS患者有效。这是第一项在特定神经源性患者群体中使用索利那新并采用神经源性疾病特异性生活质量结局指标（MS-QoL 54）的研究。
